Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term randomized open-label study of TS-142 in Japanese patients with insomnia disorder
jRCT2031220208Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of vornorexant in Insomnia (2 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: Adverse events. Started Oct 2022; status: completed.
02
Drugs
vornorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on jRCT2031220208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220208.